Weekly dosage of docetaxel combined with cisplatin and 5-fluorouracil in the treatment of advanced gastric cancer.
- Author:
Ai-Min ZHANG
1
;
Shen YE
Author Information
- Publication Type:Clinical Trial
- MeSH: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; administration & dosage; Cisplatin; administration & dosage; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; administration & dosage; Humans; Infusions, Intravenous; Male; Middle Aged; Stomach Neoplasms; drug therapy; mortality; Taxoids; administration & dosage; Treatment Outcome
- From: Journal of Southern Medical University 2007;27(10):1555-1557
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo observe the effects and toxicity of docetaxel given once weekly combined with cisplatin and 5-fluororacil in the treatment of advanced gastric cancer (AGC).
METHODSThirty-one patients with AGC were given docetaxel at 35 mg/m square by intravenous infusion completed in 1 h on the 1st, 8th and 15th days. Cisplatin was given at 20 mg/m square for 4 h between the 2nd and 6th days, during which time 5-fluororacil was also given at 750 mg/m square for 24 h. One treatment cycle lasted for 28 days and 2 consecutive cycles were administered.
RESULTSIn the 31 patients available for therapeutic effect evaluation, the overall effective rate was 48.4%. The effective rate in patients without previous treatments was 64.7% (CR in 2 cases), and 28.6% in the retreated patients. The median TTP, median survival time and one-year survival rate were 6 months, 11 months and 41.9%, respectively. The main toxic reactions of the combined treatment were myelosuppression, gastrointestinal tract reaction and alopecia of mostly grade 1 or 2.
CONCLUSIONWeekly dosage of docetaxel combined with cisplatin and 5-fluororacil is an effective regimen for AGC with only mild toxic reactions and good patient tolerance.
